Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | HD17: PET guided omission of radiotherapy in Hodgkin lymphoma

Peter Borchmann • 3 Jun 2020
EHA 2020
Hodgkin Lymphoma Lymphoma Bleomycin Dacarbazine Doxorubicin Vinblastine
HD17

Peter Borchmann, MD , University Hospital Cologne, Cologne, Germany, discusses HD17 (NCT01356680), a Phase III trial of PET-guided omission of radiotherapy in early-stage unfavorable Hodgkin lymphoma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Peter Borchmann

1:34
PET-guided treatment: the new standard of care in Hodgkin lymphoma?
Peter Borchmann • 15 Jun 2023
1:26
Promising results from the SWOG S1826 trial: nivo-AVD versus BV-AVD in patients with cHL
Peter Borchmann • 15 Jun 2023
2:27
Insights into the BrECADD regimen in HL & results from the GHSG HD21 study
Peter Borchmann • 15 Jun 2023
5:02
HD21: treatment-related morbidity in patients with Hodgkin lymphoma treated with BrECADD vs eBEACOPP
Peter Borchmann • 12 Dec 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals